ATX

3.45%

15.0¢ amplia therapeutics limited

Motley & Gas go well together ...regarding T Price tell the...

First 113 Last

Share
Profile

Follow
duty

15,036 Posts.

95

01/02/17

00:47

Post #: 22271606
Share

Originally posted by itsagas ↑

Pete 70...these people won't listen..

Out just now part of Article by Tom Richardson..Mötley Fool.

Shares in Aussie biotech hopeful Innate Immunotherapeutics Ltd (ASX: IIL) have gone into orbit today despite the company revealing a quarterly cash flow statement that hardly inspires evangelical-like confidence in the future.

For the quarter ending December 31 2016 it delivered a net operating cash loss of $1.78 million, with just $6 million of cash left on its balance sheet at the end of the period.

What must be exciting investors is the potential of what the company claims are its unique drugs that could be used for the treatment of patients suffering from multiple sclerosis. It’s a condition that attacks a patient’s immune system and Innate Immunotherapeutics currently has a Phase II B clinical trial underway to part test its MIS416 drug’s efficacy in treating patients with secondary progressive multiple sclerosis.

Despite the business having nothing in the way of operating revenues the market is now ascribing it a valuation around $173 million, after shares rocketed 50% to $1.17 today.

Mysterious price action

On January 27 the stock hit a high of $1.83 only to close at 78 cents just one trading day later on January 30 in some wild price action that has already attracted the attention of the regulator in terms of an ASX price query.

The trading action is also seeing relatively heavy volumes which makes the price action all the more mysterious, with the most likely explanation that it is being driven by day traders seeking to make quick profits.

For long-term investors it looks a business to watch from the sidelines and not just because of the huge share price swings increasing the likelihood of a visit to the burns clinic.

Anyone considering an investment should note that the company is currently is still at a relatively early investment stage, with just one product at Phase II trial status. This means it probably has expensive and time consuming Phase III trials ahead of it before it could seek any commercial approval to sell its drugs.

Evidently with multiple hurdles to jump, no revenues, and significant costs ahead, it looks an extremely speculative investment prospect and one to watch from the sidelines in my opinion.

Of course if it does ever get approval for its drugs it will be great news for potential patients and the company’s investors, although that seems a long way off for now.

Expand

Motley & Gas go well together ...regarding T Price tell the whole story ..when Co's raise Money ..of course they go to the best source available at the time ...everybody gets s discount when raising $ ...hes done nothing wrong its all Ps & wind

IIL Price at posting: $1.24 Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

BUX

Buxton projects new graphite province discovery at WA Narryer play

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

There are more pages in this discussion • 36 more messages in this thread...

First 113 Last

Add ATX (ASX) to my watchlist

(20min delay)
Last 15.0¢		Change 0.005(3.45%)		Mkt cap ! $41.21M

Open	High	Low	Value	Volume
15.5¢	16.0¢	15.0¢	$55.88K	361.3K

Buyers (Bids)

No.	Vol.	Price($)
3	94946	15.0¢

Sellers (Offers)

Price($)	Vol.	No.
16.0¢	56159	1

View Market Depth

No.	Vol.	Price($)
3	94946	0.150
3	42061	0.145
11	640690	0.140
8	277010	0.135
4	130715	0.130

Price($)	Vol.	No.
0.160	56159	1
0.165	7500	2
0.175	100000	1
0.180	1383867	3
0.185	69568	1

Last trade - 16.10pm 04/10/2024 (20 minute delay)

ATX (ASX) Chart

Motley & Gas go well together ...regarding T Price tell the...

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Buxton projects new graphite province discovery at WA Narryer play

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BCI reaches close of funding facility for salt-first part of Mardie project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Motley & Gas go well together ...regarding T Price tell the...

Top Stories

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Buxton projects new graphite province discovery at WA Narryer play

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BCI reaches close of funding facility for salt-first part of Mardie project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News